Nasal polyps are soft, noncancerous growths on the lining of the nose or sinuses. These growths, while painless, can cause blockages that prevent the sinuses from draining properly. This can make it ...

HOUSTON -- Treatment with omalizumab (Xolair) was associated with improved endoscopic, clinical, and patient-reported outcomes in two parallel phase III studies in patients with steroid-refractory ...

Nasal polyp development, treatment, and recurrence were topics up for discussion in this year’s most popular nasal polyps–related content. Nasal polyp development, treatment, and recurrence, as well ...

The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

Please provide your email address to receive an email when new articles are posted on . A combined set of clinical and biological variables predicted polyp recurrence and severity among patients who ...

Antrochoanal polyps (ACPs) are benign, solitary lesions that originate from the mucosa of the maxillary sinus and extend into the nasal cavity towards the choana. They can present with unilateral ...

Patients with comorbid chronic rhinosinusitis (CRS) with nasal polyps and asthma reported significant reductions in endoscopic sinus score and severity, as well as decreased dosage of oral steroids ...

Please provide your email address to receive an email when new articles are posted on . Wenyi Chen, of the department of otolaryngology-head and neck surgery at Third Affiliated Hospital of Sun ...

Nasal polyps are soft, painless, noncancerous growths on the lining of your nasal passages or sinuses. They hang down like teardrops or grapes. They result from chronic inflammation due to asthma, ...

The reimbursement rates for many ASC procedures have benefited and will benefit under the new Medicare payment system. One such procedure seeing a noticeable reimbursement boost is endoscopy with ...

WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...